论文信息 - Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française - 字舞流文

Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française

M. Boisson | Y. Allanore | J. Avouac | C. Frantz | A. Combier | E. Descamps | S. Wanono | O. Fogel | C. Bottois | X. Ayral | L. Poiroux

[1] Rishi Gupta,et al. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic , 2020, Rheumatology.

[2] J. L. Garrido-Castro,et al. Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients , 2020, Joint Bone Spine.

[3] K. Pavelka,et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries , 2018, RMD Open.

[4] M. Genovese,et al. Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate , 2011, Arthritis and rheumatism.